<?xml version="1.0" encoding="UTF-8"?>
<p>Despite their widespread and increasing transmission, there is still a poor understanding of global economic impact of viral diseases, which makes difficult to evaluate the societal costs and the cost-effectiveness of preventive efforts. The issue of estimating a general impact of viral infections involves several aspects that hinder this approach, namely: the variety of viral infections, the incidence of associated co-morbidities, social and psychological issues having economic repercussions (hidden costs), the variety of treatments (only direct-acting antiviral (DAA) and vaccinations can be used in the evaluation) and the presence of negative externalities [
 <xref rid="B2-pharmaceutics-12-00171" ref-type="bibr">2</xref>], meaning that the disease consequences are not limited to their patients infected or potentially but also to the related families who may experience social distress as well. Also, human mobility and long-distance trade have increased; ever-larger cities, often girded with slums, have become highways for microbial traffic; poverty perpetuates vulnerability to infectious disease; and sexual practices, drug injecting, intensified food production and much modern medical technology all create new “audience” for microbial opportunism, and new management issues for public health decision makers [
 <xref rid="B1-pharmaceutics-12-00171" ref-type="bibr">1</xref>].
</p>
